Thus, this marker in our model is critical for early-stage lung cancer, and additional studies are needed to investigate potential targets to reverse the inhibition of GJA1 function observed in response to the MCA/LMW PAH mixture/B[a]P treatment. This evidence concerns the gene GJA1 and lung carcinoma.